ArticleKidney international2021
Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis.
Article in Kidney international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 143 citations in OpenAlex.
- MHC class II and PLA2R investigating the epitope presentation deficits driving antibody production in membranous nephropathy.International urology and nephrology · 2026Review
- Multiplexed Detection of Membranous Nephropathy Antigens by Multi-Reaction Monitoring Mass Spectrometry.Kidney international reports · 2026Article
- Complement Profiling in Glomerular Disease: Insights from Laser Microdissection and Mass Spectrometry.Clinical journal of the American Society of Nephrology : CJASN · 2026Review
- Proteomic Profiling of Complement Components in Glomerular Disease.Laboratory investigation; a journal of technical methods and pathology · 2026Article
- Membranous Nephropathy: Antigenic Landscape and a Novel Pathogenetic Model.International journal of molecular sciences · 2026Review
- Contemporary review of primary membranous nephropathy.Frontiers in immunology · 2026Review
- Liver-kidney crosstalk in primary biliary cholangitis: insights into the mechanisms of renal involvement.Frontiers in immunology · 2026Review
- Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies.Frontiers in immunology · 2026Review
- Beyond the alarm: unveiling the multifaceted role of IL-33 in kidney disease.Frontiers in immunology · 2026Review
- Autoantibody repertoire in lupus nephritis: from pathogenic mechanisms to clinical integration for precision decision-making.Frontiers in immunology · 2026Review
- Evolution of idiopathic membranous nephropathy to class v lupus nephritis: a case report and literature review.Frontiers in medicine · 2026Article
- Biomimetic fractal topography enhances podocyte maturation in vitro.Nature communications · 2025Article
- Long COVID is associated with female sex; Anti-NCAM1 autoantibodies are absent in patients with long COVID.IBRO neuroscience reports · 2025Article
- Serum proteome analysis detects early molecular signatures of disease progression in IgA nephropathy.Clinical kidney journal · 2025Article
- Not So Benign: Revisiting Pure Membranous Lupus Nephritis.Journal of personalized medicine · 2025Review
- Unexpected heterogeneity and tissue-specific properties of the thymic hematopoietic antigen-presenting cell network.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Autoantibodies and Inflammation in Schizophrenia.Psychiatry and clinical neurosciences · 2025Review
- Antigens in membranous nephropathy: discovery and clinical implications.Nature reviews. Nephrology · 2025Review
- Neural epidermal growth factor-like 1 expression predicts end-stage renal disease in phospholipase A2 receptor-negative membranous nephropathy: A retrospective cohort stratified by systemic lupus erythematosus.The Journal of international medical research · 2025Article
- Repeat biopsies in membranous lupus nephritis in the era of target antigen identification.Virchows Archiv : an international journal of pathology · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Membranous lupus nephritis is a frequent cause of nephrotic syndrome in patients with systemic lupus erythematosus. It has been shown in phospholipase A2 receptor positive membranous nephropathy that known antibodies can be detected within sera, determination of the target autoantigen can have diagnostic significance, inform prognosis, and enable non-invasive monitoring of disease activity. Here we utilized mass spectrometry for antigen discovery in laser captured microdissected glomeruli from formalin-fixed paraffin embedded tissue and tissue protein G immunoprecipitation studies to interrogate immune complexes from frozen kidney biopsy tissue. We identified neural cell adhesion molecule 1 (NCAM1) to be a target antigen in some cases of membranous lupus nephritis and within rare cases of primary membranous nephropathy. The prevalence of NCAM1 association was 6.6% of cases of membranous lupus nephritis and in 2.0% of primary membranous nephropathy cases. NCAM1 was found to colocalize with IgG within glomerular immune deposits by confocal microscopy. Additionally, serum from patients with NCAM1-associated membranous nephropathy showed reactivity to NCAM1 recombinant protein on Western blotting and by indirect immunofluorescence assay, demonstrating the presence of circulating antibodies. Thus, we propose that NCAM1 is a target autoantigen in a subset of patients with membranous lupus nephritis. Future studies are needed to determine whether anti-NCAM1 antibody levels correlate with disease activity or response to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.